WO2015001163A3 - Nanopartículas lipídicas para la cicatrización de heridas - Google Patents

Nanopartículas lipídicas para la cicatrización de heridas Download PDF

Info

Publication number
WO2015001163A3
WO2015001163A3 PCT/ES2014/070541 ES2014070541W WO2015001163A3 WO 2015001163 A3 WO2015001163 A3 WO 2015001163A3 ES 2014070541 W ES2014070541 W ES 2014070541W WO 2015001163 A3 WO2015001163 A3 WO 2015001163A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid nanoparticles
healing wounds
relates
lipid
wounds
Prior art date
Application number
PCT/ES2014/070541
Other languages
English (en)
French (fr)
Other versions
WO2015001163A2 (es
Inventor
Eusebio Gainza Lafuente
Garazi Gainza Lucea
Silvia Villullas Rincón
Marta Pastor Navarro
Oihane Ibarrola Moreno
Gorka Alonso Hornes
Angel DEL POZO PÉREZ
Rosa María Hernández Martín
Manuela Igartua Olaechea
José Luis PEDRAZ MUÑOZ
Original Assignee
Praxis Biopharma Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015001163(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Praxis Biopharma Research Institute filed Critical Praxis Biopharma Research Institute
Priority to BR112016000092A priority Critical patent/BR112016000092A2/pt
Priority to CN201480048700.6A priority patent/CN105611916A/zh
Priority to ES14761385.5T priority patent/ES2658402T3/es
Priority to RU2016103490A priority patent/RU2662097C2/ru
Priority to US14/902,766 priority patent/US10206886B2/en
Priority to JP2016522672A priority patent/JP6214764B2/ja
Priority to EP14761385.5A priority patent/EP3023105B1/en
Publication of WO2015001163A2 publication Critical patent/WO2015001163A2/es
Publication of WO2015001163A3 publication Critical patent/WO2015001163A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a nanopartículas lipídicas que comprenden un factor de crecimiento y/o un lípido antimicrobiano y a su método de preparación. Asimismo, se refiere a composiciones farmacéuticas que comprenden dichas nanopartículas lipídicas y un vehículo farmacéuticamente aceptable. Por último, se refiere a dicha composición farmacéutica para su uso como medicamento y para su uso para promover la cicatrización de heridas, en particular mediante administración tópica.
PCT/ES2014/070541 2013-07-04 2014-07-03 Nanopartículas lipídicas para la cicatrización de heridas WO2015001163A2 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR112016000092A BR112016000092A2 (pt) 2013-07-04 2014-07-03 nanopartículas lipídicas para a cicatrização de feridas
CN201480048700.6A CN105611916A (zh) 2013-07-04 2014-07-03 用于愈合伤口的脂质纳米颗粒
ES14761385.5T ES2658402T3 (es) 2013-07-04 2014-07-03 Nanopartículas lipídicas para la cicatrización de heridas
RU2016103490A RU2662097C2 (ru) 2013-07-04 2014-07-03 Липидные наночастицы для ранозаживления
US14/902,766 US10206886B2 (en) 2013-07-04 2014-07-03 Lipid nanoparticles for wound healing
JP2016522672A JP6214764B2 (ja) 2013-07-04 2014-07-03 創傷治癒のための脂質ナノ粒子
EP14761385.5A EP3023105B1 (en) 2013-07-04 2014-07-03 Lipid nanoparticles for healing wounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130382275 EP2821077A1 (en) 2013-07-04 2013-07-04 Lipid nanoparticles for wound healing
EP13382275.9 2013-07-04

Publications (2)

Publication Number Publication Date
WO2015001163A2 WO2015001163A2 (es) 2015-01-08
WO2015001163A3 true WO2015001163A3 (es) 2015-04-09

Family

ID=49596224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2014/070541 WO2015001163A2 (es) 2013-07-04 2014-07-03 Nanopartículas lipídicas para la cicatrización de heridas

Country Status (8)

Country Link
US (1) US10206886B2 (es)
EP (2) EP2821077A1 (es)
JP (1) JP6214764B2 (es)
CN (1) CN105611916A (es)
BR (1) BR112016000092A2 (es)
ES (1) ES2658402T3 (es)
RU (1) RU2662097C2 (es)
WO (1) WO2015001163A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
WO2017098474A1 (en) * 2015-12-09 2017-06-15 Universidade Do Minho Antimicrobial peptide-loaded hyaluronic acid-based formulations, method of production and uses thereof
US20200268679A1 (en) * 2017-11-03 2020-08-27 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
RU2018114533A (ru) * 2018-04-19 2019-10-21 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Композиция на основе твердых липидных частиц, обладающая свойством направленной доставки для лечения вирусных заболеваний (варианты)
CN111743799B (zh) * 2020-07-07 2023-01-10 台湾美联生物科技有限公司 纳米级固态脂质载体及制备方法和包含其的化妆品
WO2022101921A1 (en) * 2020-11-16 2022-05-19 Delhi Pharmaceutical Sciences & Research University Topical nanolipidic gel formulation for diabetic foot ulcer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039700A1 (en) * 1998-02-06 1999-08-12 Eurand International S.P.A. Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
WO2005120469A1 (en) * 2004-06-09 2005-12-22 Maria Rosa Gasco Lipid nanoparticles as vehicles for nucleic acids, process for their preparation and use
GB2415903A (en) * 2004-07-07 2006-01-11 Ethicon Inc Pharmaceutical preparation which promotes wound healing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US5219998A (en) 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
BRPI9905430B1 (pt) 1999-12-01 2015-08-25 Ana Cristina Marchiorato Carneiro Corrêa Dispositivo de medição de hidrogênio permeado em estrutura metálica e processo de montagem externa e interna do mesmo em uma estrutura metálica.
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
WO2012031205A2 (en) * 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
ES2386177B1 (es) * 2010-09-21 2013-09-23 Lipotec, S.A. Nanocapsulas conteniendo microemulsiones
KR20140031227A (ko) * 2011-03-24 2014-03-12 레오 파마 에이/에스 지질 나노입자들 및 코르티코스테로이드 또는 비타민 ｄ 유도체를 포함하는 조성물
WO2015001160A1 (es) * 2013-07-03 2015-01-08 Biopraxis Research Aie Nanopartícula lipídica de polimixina
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039700A1 (en) * 1998-02-06 1999-08-12 Eurand International S.P.A. Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
WO2005120469A1 (en) * 2004-06-09 2005-12-22 Maria Rosa Gasco Lipid nanoparticles as vehicles for nucleic acids, process for their preparation and use
GB2415903A (en) * 2004-07-07 2006-01-11 Ethicon Inc Pharmaceutical preparation which promotes wound healing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE ET AL: "Apoptotic epidermal growth factor conjugated block co-polymer micells as a nanotechnology platform for targeted combination therapy.", MOL. PHARMACEUTICS, vol. 4, no. 5, 2007 - 2007, pages 769 - 781, XP002719017 *
MANJUNATH K ET AL: "Solidlipidnanoparticles as drug delivery systems", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, BARCELONA : PROUS SCIENCE - THOMSON REUTERS, 1979-2010ANFANGS: BARCELONA : PROUS, ES, vol. 27, no. 2, 1 March 2005 (2005-03-01), pages 127 - 144, XP009175638, ISSN: 0379-0355 *

Also Published As

Publication number Publication date
ES2658402T3 (es) 2018-03-09
EP2821077A1 (en) 2015-01-07
EP3023105A2 (en) 2016-05-25
US20160199447A1 (en) 2016-07-14
WO2015001163A2 (es) 2015-01-08
US10206886B2 (en) 2019-02-19
BR112016000092A2 (pt) 2017-12-12
JP6214764B2 (ja) 2017-10-18
JP2016523884A (ja) 2016-08-12
RU2662097C2 (ru) 2018-07-23
RU2016103490A (ru) 2017-08-09
CN105611916A (zh) 2016-05-25
EP3023105B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
WO2015001163A3 (es) Nanopartículas lipídicas para la cicatrización de heridas
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
EP3072506A4 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
IN2015DN01727A (es)
EP3067059A4 (en) Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
HK1222337A1 (zh) 用於施加藥物活性成分或化妝品活性成分的局部組合物和載體
EP3068436A4 (en) Topical pharmaceutical, cosmetic and disinfectant compositions comprising phosphatidylcholine
EP3031465A4 (en) Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
WO2012155226A8 (pt) Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14761385

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15311853

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2016522672

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14902766

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016000092

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2014761385

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014761385

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016103490

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112016000092

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016000092

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160104